Showing results (51-60 of 64) with videos related to
Sort By:
Pageof 7
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 13, 2025
Pharmacokinetics and protein binding of cholesterol-conjugated heteroduplex oligonucleotideYukitake Yoshioka, Syunsuke Yamamoto, Kosuke Kusamori, et al.Endocrine Journal|February 19, 2025
Assessing the potential of high-mobility group AT-hook 2 immunohistochemical staining as a prognostic marker of metastatic recurrence in follicular thyroid cancer: a retrospective cohort studyYuka Ito, Junko Sakumoto, Hideki Hirabayashi, et al.Bioorganic & Medicinal Chemistry|September 18, 2017
Highly potent antiobesity effect of a short-length peptide YY analog in miceNaoki Nishizawa, Ayumu Niida, Yusuke Adachi, et al.Journal of Medicinal Chemistry|June 29, 2017
Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated PeptideYoko Kanematsu-Yamaki, Naoki Nishizawa, Tomoko Kaisho, et al.The Journal of Pharmacology and Experimental Therapeutics|October 23, 2022
Quantitative Model Analysis and Simulation of Pharmacokinetics and Metastasis-Associated Lung Adenocarcinoma 1 RNA Knockdown Effect After Systemic Administration of Cholesterol-Conjugated DNA/RNA Heteroduplex Oligonucleotide Crossing Blood-Brain Barrier of MiceAkihiko Goto, Syunsuke Yamamoto, Tomoko Igari, et al.Journal of Medicinal Chemistry|January 7, 2016
Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one DerivativesHideyuki Igawa, Masashi Takahashi, Keiko Kakegawa, et al.Bioorganic & Medicinal Chemistry|December 28, 2017
Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivativesAyumu Niida, Yoko Kanematsu-Yamaki, Tomoko Asakawa, et al.The Journal of Pharmacology and Experimental Therapeutics|February 17, 2026
Preclinical characterization of pharmacokinetics, enzyme occupancy, and pharmacodynamics of soticlestat (TAK-935), a novel cholesterol 24-hydroxylase inhibitorMaki Miyamoto, Toshiya Nishi, Tatsuki Koike, et al.Clinical and Translational Science|April 14, 2022
Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugsTatsuki Mochizuki, Yasunori Aoki, Takashi Yoshikado, et al.Clinical Pharmacology and Therapeutics|March 16, 2022
Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug InteractionsTatsuki Mochizuki, Maciej J Zamek-Gliszczynski, Kenta Yoshida, et al.Pageof 7